Company news: mobile ad budgets continue to grow
Johnson & Johnson's Risperdal marketing headache continues. The company's billion-dollar settlement has been rejected by the Feds who are looking for a larger settlement, reports the Wall Street Journal. This is just the latest in a change of upsets for the company which has seen its CEO Weldon get knocked down a peg and its reputation get repeatedly dinged by product recalls. J&J's Janssen unit was accused of fraudulently marketing its drug Risperdal in Texas. The company cited the litigation as one of its special pre-tax items during the fourth quarter.